Has Roger On received payments from drug or device companies?

Yes. Drug and device makers reported $5,062 in general payments to Roger On across 195 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Roger On did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Roger On come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Roger On

Cardiovascular Disease · Sherman Oaks, CANPI 1255334769

Payments from drug & device makers

$5,062in general payments, 2019–2025

Across 195 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boehringer Ingelheim$820
E.r. Squibb & Sons, L.L.C.$806
Johnson & Johnson$410
AstraZeneca$338
Novartis$297
Pfizer$285
plus $2K from 29 others

What the payments were for

Food & beverage$5,01499%
Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boehringer Ingelheim	26	$820
E.r. Squibb & Sons, L.L.C.	23	$806
Johnson & Johnson	18	$410
AstraZeneca	11	$338
Novartis	16	$297
Pfizer	12	$285
Amgen	10	$226
Akcea Therapeutics, Inc.	7	$215
Lantheus Medical Imaging, Inc.	3	$181
Edwards Lifesciences	6	$153
Kowa Pharmaceuticals America, Inc.	5	$129
Lundbeck LLC	5	$129
Actelion Pharmaceuticals US, Inc.	4	$97
Amarin Pharma, Inc.	4	$90
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	5	$88
Merck	4	$87
Takeda Pharmaceuticals U.S.A., Inc.	4	$85
Novo Nordisk	4	$85
Alnylam Pharmaceuticals Inc.	4	$84
Abbott	2	$50
Bardy Diagnostics, Inc.	2	$46
IBSA Pharma Inc.	2	$40
Sanofi-aventis U.S. LLC	2	$38
Bausch Health US, LLC	2	$35
Insulet Corporation	2	$34
Portola Pharmaceuticals, LLC	2	$33
Mannkind Corporation	2	$30
Lilly USA, LLC	1	$28
Otsuka America Pharmaceutical, Inc.	1	$25
Irhythm Technologies, Inc.	1	$22
Regeneron Healthcare Solutions, Inc.	1	$19
Siemens Medical Solutions USA, Inc.	1	$17
Teva Pharmaceuticals USA, Inc.	1	$15
Tactile Systems Technology Inc	1	$15
Circassia Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,062 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California →

Other cardiovascular disease in Sherman Oaks

Ted LoveHillsborough$102.8M
Matthew BudoffTorrance$11.3M
Lori DanielsSan Diego$10.2M
Paul KurthSanta Barbara$6.1M
Michael BlumSan Francisco$5.5M
Tony ChouSan Francisco$5.2M
Jason RogersSacramento$5.1M
Yu-Ping WangStanford$3.8M
Yogesh PaliwalPomona$3.3M
Farhad RafiiWest Hills$3.2M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →